Cardiovascular profile of loratadine

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 197-199

  Hey, J A ^a   Affrime, M ^a   Cobert, B ^a   Kreutner, W ^a   Cuss, F M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular; Loratadine; Non sedating antihistamine

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CIMETIDINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; ERYTHROMYCIN; KETOCONAZOLE; LORATADINE; POTASSIUM CHANNEL; TERFENADINE;

ARTICLE; CARDIOVASCULAR EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; GUINEA PIG; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; TORSADE DES POINTES;

EID: 0032784839     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3197.x     Document Type: Article

References (16)

1. Ko CM, Ducic I, Fan J, Shuba YM, Morad M. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 1997;281:233-44.
2. Ducic J, Ko MC, Shuba Y, Morad M. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Card Pharmacol 1997; 30:42-54.
3. Lacerda AE, Roy M-L, Lewis ER, Rampe D. Interactions of the nonsedating antihistamine loratadine with a Kvl.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52:314-22.
4. 1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54:113-21.
5. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmias: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
6. Roy M-L, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circul 1996; 94:817-23.
7. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77-80.
8. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
9. Honig PK, Wortham DC, Zamini K, Connor DP, Mullin JC, Cantilena LR. Terfenadine -ketoconazole interaction. J Am Med Assoc 1993; 269:1513-8.
10. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Form Med Assoc 1997; 96:144-6.
11. Hey JA, del Prado M, Cuss FM, et al. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamine in guinea pigs. Clin Exp Allergy 1995; 25:974-84.
12. Hey JA, del Prado M, Sherwood J, Kreutner W, Egan RW. Comparative analysis of the cardiotoxic proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arz Forsch/ Drug Res 1996; 46:153-8.
13. Lorber R, Danzig M, Brannan M. Loratadine (L) does not affect QTc interval nor produce torsades de pointes type arrhythmias. Allergy 1997; 37:207.
14. Brannan MD, Affrime MB, Reidenberg P, Radwanski E, Lin C-C. Evaluation of the pharmacokinetics and electrocardiographic pharmacokinetics of loratadine with the concomitant administration of cimetidine. Pharmacother 1994; 14:347.
15. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin C-C, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic parameters following 10 days of concomitant loratadine with ketoconazole. J Clin Pharmacol 1994; 34:1016.
16. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin C-C, Cayen MN, Affrime MB. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-78.